← Back to Search

Biological Response Modifier

Atacicept Dose for Lupus Nephritis (COMPASS Trial)

Phase 3
Waitlist Available
Research Sponsored by Vera Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 52 and 104
Awards & highlights

COMPASS Trial Summary

This trial will look at how a drug affects kidney function in people with Lupus Nephritis.

Eligible Conditions
  • Lupus Nephritis

COMPASS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 52 and 104
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 52 and 104 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Renal Response as definedas UPCR ≤0.5 mg/mg, and eGFR ≥60 mL/min/1.73 m^2 or eGFR <60 mL/min/1.73 m^2 with no confirmed decrease from baseline of >20%
Secondary outcome measures
Renal Response at Week 104
Renal Response with alternative success criteria
Time to Death or Renal-Related Event
+1 more

Side effects data

From 2009 Phase 2 trial • 256 Patients • NCT00430495
18%
Headache
8%
Nausea
6%
Urinary tract infection
6%
Diarrhoea
6%
Constipation
5%
Nasopharyngitis
5%
Hypertension
5%
Upper respiratory tract infection
3%
Rheumatoid arthritis
2%
Gamma-glutamyltransferase increased
2%
Non-cardiac chest pain
2%
Drug hypersensitivity
2%
Iron deficiency anaemia
2%
Fibrin D dimer increased
2%
Relapsing fever
2%
Hyperthyroidism
2%
Femur fracture
2%
Anaemia
2%
Fallopian tube cyst
2%
Pyrexia
2%
Humerus fracture
2%
Pelvic fracture
2%
Upper limb fracture
2%
Diverticular perforation
2%
Intestinal obstruction
100%
80%
60%
40%
20%
0%
Study treatment Arm
Atacicept 25 mg
Placebo
Atacicept 75 mg
Atacicept 150 mg

COMPASS Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Atacicept DoseExperimental Treatment1 Intervention
Atacicept Dose once weekly subcutaneous (SC) Injection
Group II: Placebo to match AtaciceptPlacebo Group1 Intervention
Placebo to match Atacicept once weekly subcutaneous (SC) injection
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atacicept
2006
Completed Phase 2
~600

Find a Location

Who is running the clinical trial?

Vera Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
406 Total Patients Enrolled
Joanne CurleyStudy DirectorChief Development Officer
1 Previous Clinical Trials
376 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the Federal Drug Administration cleared Atacicept Dose for patient use?

"There is some evidence suggesting Atacicept Dose is effective and it has received multiple rounds of safety testing, so our team rates its safety at a 3."

Answered by AI

Does this research project restrict participants to those over the age of 75 years?

"The age restrictions for this clinical trial are that patients must be over 18 but under 75 years old."

Answered by AI

Are investigators looking for participants at this time?

"Yes, this study is ongoing and actively recruiting patients according to the information available on clinicaltrials.gov. The listing for the trial was first posted on November 2nd, 2020 and updated last on November 7th, 2020."

Answered by AI

In how many different medical hospitals is this clinical trial being run today?

"In addition to 26 other locations, this study is being conducted out of Vera Site # 0149 in Summit, New jersey, Vera Site # 0143 in New Haven, Connecticut, and Vera Site # 0135 in Northridge, California."

Answered by AI

Could I join this experiment?

"This study is looking for 360 participants who have lupus nephritis and meet the following criteria: 18-75 years of age, diagnosis of SLE, male or female, ability to understand and sign a written informed consent form, biopsy-proven active LN, willing to take oral MMF for the duration of the study."

Answered by AI

How many test subjects are involved in this experiment?

"The sponsor, Vera Therapeutics, Inc., needs to enroll 360 eligible patients from multiple clinical trial sites in order to carry out the study. For example, Vera Site # 0149 located in Summit, New jersey and Vera Site # 0143 situated in New Haven, Connecticut."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
2022. "Atacicept in Subjects With Active Lupus Nephritis (COMPASS)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05609812.
~198 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top